

**Clinical trial results:****A Randomized, Multicenter, Open-label, Parallel Group Study in Postmenopausal Women With Osteoporosis to Evaluate the Noninferiority of Subject-administered Romosozumab via Autoinjector/Pen vs Healthcare Provider-administered Romosozumab via Prefilled Syringe****Summary**

EudraCT number	2017-003512-40
Trial protocol	GB PL
Global end of trial date	08 January 2020

**Results information**

Result version number	v1 (current)
This version publication date	21 November 2020
First version publication date	21 November 2020

**Trial information****Trial identification**

Sponsor protocol code	20150120
-----------------------	----------

**Additional study identifiers**

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03432533
WHO universal trial number (UTN)	-

Notes:

**Sponsors**

Sponsor organisation name	Amgen Inc.
Sponsor organisation address	One Amgen Center Drive, Thousand Oaks, CA, United States,
Public contact	IHQ Medical Info-Clinical Trials, Amgen (EUROPE) GmbH, MedInfoInternational@amgen.com
Scientific contact	IHQ Medical Info-Clinical Trials, Amgen (EUROPE) GmbH, MedInfoInternational@amgen.com

Notes:

**Paediatric regulatory details**

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	08 January 2020
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	08 January 2020
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The primary objective of this study is to evaluate the noninferiority of a 6-month treatment with romosozumab 210 mg administered subcutaneously (SC) once monthly (QM) in postmenopausal women with osteoporosis either by subject self-administration with autoinjector (AI)/pen or by healthcare provider (HCP) administration with prefilled syringe (PFS).

Protection of trial subjects:

This study was conducted in accordance with International Council for Harmonisation (ICH) Good Clinical Practice (GCP) and local regulations/guidelines. The investigator or his/her designee informed the subject of all aspects pertaining to the subject's participation in the study before any screening procedures were performed.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	06 February 2018
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	United States: 95
Country: Number of subjects enrolled	United Kingdom: 32
Country: Number of subjects enrolled	Poland: 156
Worldwide total number of subjects	283
EEA total number of subjects	188

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	74

From 65 to 84 years	197
85 years and over	12

## Subject disposition

### Recruitment

Recruitment details:

Participants were enrolled at 36 centers in Poland, United Kingdom, and United States.

### Pre-assignment

Screening details:

Participants were randomized in a 1:1 ratio.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

<b>Arm title</b>	Romosozumab 210 mg QM: PFS
------------------	----------------------------

Arm description:

During the open-label treatment period, participants received 210 mg romosozumab subcutaneously (SC) once a month (QM) by health care provider (HCP) administration with pre-filled syringe (PFS).

Arm type	Experimental
Investigational medicinal product name	romosozumab
Investigational medicinal product code	AMG785
Other name	Evenity
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subconjunctival use, Subcutaneous use

Dosage and administration details:

210 mg romosozumab SC QM by HCP administration with 2 PFS

<b>Arm title</b>	Romosozumab 210 mg QM: AI/Pen
------------------	-------------------------------

Arm description:

During the open-label treatment period, participants received 210 mg romosozumab SC QM by self-administration with autoinjector (AI)/pen.

Arm type	Experimental
Investigational medicinal product name	romosozumab
Investigational medicinal product code	AMG785
Other name	Evenity
Pharmaceutical forms	Solution for injection in pre-filled pen
Routes of administration	Subcutaneous use

Dosage and administration details:

210 mg romosozumab SC QM by self-administration with 2 AI/Pens

<b>Number of subjects in period 1</b>	Romosozumab 210 mg QM: PFS	Romosozumab 210 mg QM: AI/Pen
Started	141	142
Completed 6-Month Treatment Period	136	137
Completed	126	131
Not completed	15	11
Consent withdrawn by subject	14	9
Lost to follow-up	1	2

## Baseline characteristics

### Reporting groups

Reporting group title	Romosozumab 210 mg QM: PFS
-----------------------	----------------------------

Reporting group description:

During the open-label treatment period, participants received 210 mg romosozumab subcutaneously (SC) once a month (QM) by health care provider (HCP) administration with pre-filled syringe (PFS).

Reporting group title	Romosozumab 210 mg QM: AI/Pen
-----------------------	-------------------------------

Reporting group description:

During the open-label treatment period, participants received 210 mg romosozumab SC QM by self-administration with autoinjector (AI)/pen.

Reporting group values	Romosozumab 210 mg QM: PFS	Romosozumab 210 mg QM: AI/Pen	Total
Number of subjects	141	142	283
Age categorical			
Units: Subjects			

Age Continuous			
Units: years			
arithmetic mean	70.3	69.5	
standard deviation	± 7.1	± 8.4	-
Sex: Female, Male			
Units:			
Female	141	142	283
Male	0	0	0
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	3	1	4
Not Hispanic or Latino	138	141	279
Unknown or Not Reported	0	0	0
Participants With Pre-Existing Anti-Romosozumab Antibodies			
Number of participants with pre-existing antibodies, including those who were binding antibody positive and those who were neutralizing antibody positive at or before baseline (BL).			
Units: Subjects			
Binding Antibody Positive at or Before BL	3	0	3
Neutralizing Antibody Positive at or Before BL	0	0	0
Binding Antibody Negative at or Before BL	138	142	280
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	1	1	2
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	1	1	2
White	139	140	279
More than one race	0	0	0
Unknown or Not Reported	0	0	0

Lumbar Spine Bone Mineral Density (BMD) T-Score			
The T-score is the BMD at the site when compared to that of a healthy thirty-year-old of the same sex. Lower scores (more negative) mean lower bone density. Normal is a T-score of $-1.0$ or higher; Osteopenia is defined as between $-1.0$ and $-2.5$ , meaning below-normal bone density without full osteoporosis; Osteoporosis is defined as $-2.5$ or lower, meaning a bone density that is two and a half standard deviations below the mean of a thirty-year-old man/woman.			
Units: T-score			
arithmetic mean	-2.69	-2.85	
standard deviation	$\pm 1.03$	$\pm 1.00$	-
Total Hip BMD T-Score			
The T-score is the BMD at the site when compared to that of a healthy thirty-year-old of the same sex. Lower scores (more negative) mean lower bone density. Normal is a T-score of $-1.0$ or higher; Osteopenia is defined as between $-1.0$ and $-2.5$ , meaning below-normal bone density without full osteoporosis; Osteoporosis is defined as $-2.5$ or lower, meaning a bone density that is two and a half standard deviations below the mean of a thirty-year-old man/woman.			
Units: T-score			
arithmetic mean	-2.29	-2.30	
standard deviation	$\pm 0.73$	$\pm 0.77$	-
Femoral Neck BMD T-Score			
The T-score is the BMD at the site when compared to that of a healthy thirty-year-old of the same sex. Lower scores (more negative) mean lower bone density. Normal is a T-score of $-1.0$ or higher; Osteopenia is defined as between $-1.0$ and $-2.5$ , meaning below-normal bone density without full osteoporosis; Osteoporosis is defined as $-2.5$ or lower, meaning a bone density that is two and a half standard deviations below the mean of a thirty-year-old man/woman.			
Units: T-score			
arithmetic mean	-2.54	-2.49	
standard deviation	$\pm 0.63$	$\pm 0.65$	-

## End points

### End points reporting groups

Reporting group title	Romosozumab 210 mg QM: PFS
Reporting group description: During the open-label treatment period, participants received 210 mg romosozumab subcutaneously (SC) once a month (QM) by health care provider (HCP) administration with pre-filled syringe (PFS).	
Reporting group title	Romosozumab 210 mg QM: AI/Pen
Reporting group description: During the open-label treatment period, participants received 210 mg romosozumab SC QM by self-administration with autoinjector (AI)/pen.	

### Primary: Percent Change From Baseline in Lumbar Spine BMD at Month 6

End point title	Percent Change From Baseline in Lumbar Spine BMD at Month 6
End point description: Percent change from baseline in BMD at the lumbar spine as measured by dual-energy x-ray absorptiometry (DXA).	
End point type	Primary
End point timeframe: Baseline, Month 6	

End point values	Romosozumab 210 mg QM: PFS	Romosozumab 210 mg QM: AI/Pen		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	135	134		
Units: percent change				
least squares mean (standard error)	9.2 ( $\pm$ 0.4)	9.0 ( $\pm$ 0.5)		

### Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Romosozumab 210 mg QM: PFS v Romosozumab 210 mg QM: AI/Pen
Number of subjects included in analysis	269
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.84
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	-0.1



Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.3
upper limit	1
Variability estimate	Standard error of the mean
Dispersion value	0.6

### Secondary: Percent Change From Baseline in Total Hip BMD at Month 6

End point title	Percent Change From Baseline in Total Hip BMD at Month 6
End point description: Percent change from baseline in BMD for total hip as measured by DXA.	
End point type	Secondary
End point timeframe: Baseline, Month 6	

End point values	Romosozumab 210 mg QM: PFS	Romosozumab 210 mg QM: AI/Pen		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	135	134		
Units: percent change				
least squares mean (standard error)	3.7 ( $\pm$ 0.6)	3.6 ( $\pm$ 0.3)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percent Change From Baseline in Femoral Neck BMD at Month 6

End point title	Percent Change From Baseline in Femoral Neck BMD at Month 6
End point description: Percent change from baseline in BMD at femoral neck as measured by DXA.	
End point type	Secondary
End point timeframe: Baseline, Month 6	

End point values	Romosozumab 210 mg QM: PFS	Romosozumab 210 mg QM: AI/Pen		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	135	134		
Units: percent change				
least squares mean (standard error)	3.4 (± 0.7)	3.6 (± 0.5)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Device-Related AEs, Discontinuations Due to AEs, and Deaths

End point title	Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Device-Related AEs, Discontinuations Due to AEs, and Deaths
-----------------	---

End point description:

AE: any untoward medical occurrence irrespective of a causal relationship with the study treatment.  
SAE: any untoward medical occurrence that meets at least 1 of the following criteria: results in death; is immediately life-threatening; requires in-patient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is a medically important serious event. Adverse device effect: any AE related to the use of a combination product or medical device. TEAEs are those AEs occurring after first dose of study drug.

End point type	Secondary
----------------	-----------

End point timeframe:

up to Month 9 (-7/+3 days)

End point values	Romosozumab 210 mg QM: PFS	Romosozumab 210 mg QM: AI/Pen		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	141	142		
Units: participants				
TEAEs: All	94	96		
TEAEs: SAEs	7	4		
TEAEs: Leading to Study Drug Discontinuation (DC)	7	15		
TEAEs: Fatal	0	0		
Treatment-Related (TR) TEAEs: All	38	59		
TR TEAEs: SAEs	0	0		
TR TEAEs: Leading to Study Drug DC	6	10		
TR TEAEs: Fatal	0	0		
Device-Related (DR) TEAEs: All	18	30		
DR TEAEs: SAEs	0	0		
DR TEAEs: Leading to Study Drug DC	0	5		
DR TEAEs: Fatal	0	0		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Participants Developing Anti-Romosozumab Antibodies

End point title	Number of Participants Developing Anti-Romosozumab Antibodies
-----------------	---

End point description:

Participants with a negative or no result at baseline (BL) developing anti-romosozumab antibodies postbaseline, including those who were binding antibody-positive or neutralizing antibody-positive postbaseline. 'Transient' positive results are those with a negative result at the participant's last time point tested within the study period.

End point type	Secondary
----------------	-----------

End point timeframe:

up to Month 9 (-7/+3 days)

End point values	Romosozumab 210 mg QM: PFS	Romosozumab 210 mg QM: AI/Pen		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	139	142		
Units: participants				
Binding Antibody Positive Post-BL	21	22		
Transient Binding Antibody Positive Post-BL	6	3		
Neutralizing Antibody Positive Post-BL	5	4		
Transient Neutralizing Antibody Positive Post-BL	0	2		

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

up to Month 9 (-7/+3 days)

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	22.0
--------------------	------

### Reporting groups

Reporting group title	Romosozumab 210 mg SC QM by PFS
-----------------------	---------------------------------

Reporting group description:

During the open-label treatment period, participants received 210 mg romosozumab subcutaneously (SC) once a month (QM) by health care provider (HCP) administration with pre-filled syringe (PFS).

Reporting group title	Romosozumab 210 mg SC QM by AI/Pen
-----------------------	------------------------------------

Reporting group description:

During the open-label treatment period, participants received 210 mg romosozumab SC QM by self-administration with autoinjector (AI)/pen.

Serious adverse events	Romosozumab 210 mg SC QM by PFS	Romosozumab 210 mg SC QM by AI/Pen	
Total subjects affected by serious adverse events			
subjects affected / exposed	7 / 141 (4.96%)	4 / 142 (2.82%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Basal cell carcinoma			
subjects affected / exposed	1 / 141 (0.71%)	0 / 142 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Glioblastoma			
subjects affected / exposed	1 / 141 (0.71%)	0 / 142 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Forearm fracture			
subjects affected / exposed	1 / 141 (0.71%)	0 / 142 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Humerus fracture			
subjects affected / exposed	1 / 141 (0.71%)	0 / 142 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound			
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	1 / 141 (0.71%)	1 / 142 (0.70%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Myocardial infarction			
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Cerebrovascular accident			
subjects affected / exposed	1 / 141 (0.71%)	0 / 142 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune system disorders			
Anaphylactic reaction			
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Colitis ischaemic			
subjects affected / exposed	1 / 141 (0.71%)	0 / 142 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Cellulitis			

subjects affected / exposed	1 / 141 (0.71%)	0 / 142 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clostridium difficile infection			
subjects affected / exposed	1 / 141 (0.71%)	0 / 142 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection			
subjects affected / exposed	1 / 141 (0.71%)	0 / 142 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 0 %

<b>Non-serious adverse events</b>	Romosozumab 210 mg SC QM by PFS	Romosozumab 210 mg SC QM by AI/Pen	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	92 / 141 (65.25%)	95 / 142 (66.90%)	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Lipoma			
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)	
occurrences (all)	0	1	
Meningioma			
subjects affected / exposed	1 / 141 (0.71%)	0 / 142 (0.00%)	
occurrences (all)	1	0	
Seborrhoeic keratosis			
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)	
occurrences (all)	0	1	
Vascular disorders			
Haematoma			
subjects affected / exposed	1 / 141 (0.71%)	0 / 142 (0.00%)	
occurrences (all)	1	0	
Hot flush			
subjects affected / exposed	2 / 141 (1.42%)	1 / 142 (0.70%)	
occurrences (all)	2	1	
Hypertension			

subjects affected / exposed	3 / 141 (2.13%)	1 / 142 (0.70%)	
occurrences (all)	3	1	
Hypotension			
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)	
occurrences (all)	0	1	
Peripheral arterial occlusive disease			
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)	
occurrences (all)	0	1	
Vasculitis			
subjects affected / exposed	1 / 141 (0.71%)	0 / 142 (0.00%)	
occurrences (all)	1	0	
General disorders and administration site conditions			
Injection site erythema			
subjects affected / exposed	25 / 141 (17.73%)	35 / 142 (24.65%)	
occurrences (all)	49	69	
Injection site pain			
subjects affected / exposed	14 / 141 (9.93%)	21 / 142 (14.79%)	
occurrences (all)	20	34	
Injection site swelling			
subjects affected / exposed	11 / 141 (7.80%)	23 / 142 (16.20%)	
occurrences (all)	13	43	
Asthenia			
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)	
occurrences (all)	0	1	
Chest pain			
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)	
occurrences (all)	0	1	
Chills			
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)	
occurrences (all)	0	1	
Cyst			
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)	
occurrences (all)	0	1	
Exercise tolerance decreased			

subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)
occurrences (all)	0	1
Fatigue		
subjects affected / exposed	1 / 141 (0.71%)	2 / 142 (1.41%)
occurrences (all)	1	4
Influenza like illness		
subjects affected / exposed	1 / 141 (0.71%)	0 / 142 (0.00%)
occurrences (all)	1	0
Injection site bruising		
subjects affected / exposed	1 / 141 (0.71%)	5 / 142 (3.52%)
occurrences (all)	2	7
Injection site discolouration		
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)
occurrences (all)	0	1
Injection site extravasation		
subjects affected / exposed	1 / 141 (0.71%)	0 / 142 (0.00%)
occurrences (all)	1	0
Injection site haemorrhage		
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)
occurrences (all)	0	1
Injection site hypersensitivity		
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)
occurrences (all)	0	1
Injection site hypertrophy		
subjects affected / exposed	1 / 141 (0.71%)	1 / 142 (0.70%)
occurrences (all)	1	1
Injection site induration		
subjects affected / exposed	2 / 141 (1.42%)	2 / 142 (1.41%)
occurrences (all)	7	2
Injection site irritation		
subjects affected / exposed	1 / 141 (0.71%)	0 / 142 (0.00%)
occurrences (all)	1	0
Injection site nodule		
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)
occurrences (all)	0	1
Injection site oedema		



subjects affected / exposed	2 / 141 (1.42%)	4 / 142 (2.82%)
occurrences (all)	2	7
Injection site pruritus		
subjects affected / exposed	6 / 141 (4.26%)	7 / 142 (4.93%)
occurrences (all)	8	15
Injection site rash		
subjects affected / exposed	0 / 141 (0.00%)	2 / 142 (1.41%)
occurrences (all)	0	2
Injection site reaction		
subjects affected / exposed	3 / 141 (2.13%)	2 / 142 (1.41%)
occurrences (all)	4	3
Injection site urticaria		
subjects affected / exposed	0 / 141 (0.00%)	2 / 142 (1.41%)
occurrences (all)	0	2
Injection site warmth		
subjects affected / exposed	2 / 141 (1.42%)	3 / 142 (2.11%)
occurrences (all)	2	6
Malaise		
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)
occurrences (all)	0	1
Mass		
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)
occurrences (all)	0	2
Non-cardiac chest pain		
subjects affected / exposed	1 / 141 (0.71%)	1 / 142 (0.70%)
occurrences (all)	1	1
Oedema peripheral		
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)
occurrences (all)	0	1
Pain		
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)
occurrences (all)	0	2
Peripheral swelling		
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)
occurrences (all)	0	1
Pyrexia		

subjects affected / exposed occurrences (all)	1 / 141 (0.71%) 1	0 / 142 (0.00%) 0	
Reproductive system and breast disorders Breast cyst subjects affected / exposed occurrences (all)	0 / 141 (0.00%) 0	2 / 142 (1.41%) 2	
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)	0 / 141 (0.00%) 0	3 / 142 (2.11%) 3	
Dysphonia subjects affected / exposed occurrences (all)	0 / 141 (0.00%) 0	1 / 142 (0.70%) 2	
Dyspnoea subjects affected / exposed occurrences (all)	1 / 141 (0.71%) 1	0 / 142 (0.00%) 0	
Nasal congestion subjects affected / exposed occurrences (all)	1 / 141 (0.71%) 1	1 / 142 (0.70%) 1	
Pulmonary fibrosis subjects affected / exposed occurrences (all)	0 / 141 (0.00%) 0	1 / 142 (0.70%) 1	
Rhinitis allergic subjects affected / exposed occurrences (all)	3 / 141 (2.13%) 3	0 / 142 (0.00%) 0	
Rhinorrhoea subjects affected / exposed occurrences (all)	0 / 141 (0.00%) 0	1 / 142 (0.70%) 1	
Psychiatric disorders Anxiety subjects affected / exposed occurrences (all)	1 / 141 (0.71%) 1	1 / 142 (0.70%) 1	
Insomnia subjects affected / exposed occurrences (all)	3 / 141 (2.13%) 3	2 / 142 (1.41%) 2	
Investigations			

Alanine aminotransferase increased subjects affected / exposed occurrences (all)	2 / 141 (1.42%) 2	0 / 142 (0.00%) 0	
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	1 / 141 (0.71%) 1	0 / 142 (0.00%) 0	
Blood creatine phosphokinase increased subjects affected / exposed occurrences (all)	0 / 141 (0.00%) 0	1 / 142 (0.70%) 1	
Blood creatinine increased subjects affected / exposed occurrences (all)	0 / 141 (0.00%) 0	1 / 142 (0.70%) 1	
Blood urea increased subjects affected / exposed occurrences (all)	0 / 141 (0.00%) 0	1 / 142 (0.70%) 1	
Chest X-ray abnormal subjects affected / exposed occurrences (all)	0 / 141 (0.00%) 0	1 / 142 (0.70%) 1	
Injury, poisoning and procedural complications Anaemia postoperative subjects affected / exposed occurrences (all)	1 / 141 (0.71%) 1	0 / 142 (0.00%) 0	
Arthropod bite subjects affected / exposed occurrences (all)	0 / 141 (0.00%) 0	1 / 142 (0.70%) 1	
Bone contusion subjects affected / exposed occurrences (all)	0 / 141 (0.00%) 0	1 / 142 (0.70%) 1	
Cataract operation complication subjects affected / exposed occurrences (all)	0 / 141 (0.00%) 0	1 / 142 (0.70%) 1	
Contusion subjects affected / exposed occurrences (all)	3 / 141 (2.13%) 4	1 / 142 (0.70%) 1	
Epicondylitis			

subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)
occurrences (all)	0	1
Facial bones fracture		
subjects affected / exposed	1 / 141 (0.71%)	1 / 142 (0.70%)
occurrences (all)	1	1
Fall		
subjects affected / exposed	1 / 141 (0.71%)	0 / 142 (0.00%)
occurrences (all)	1	0
Femur fracture		
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)
occurrences (all)	0	1
Fibula fracture		
subjects affected / exposed	1 / 141 (0.71%)	0 / 142 (0.00%)
occurrences (all)	1	0
Foot fracture		
subjects affected / exposed	2 / 141 (1.42%)	2 / 142 (1.41%)
occurrences (all)	2	2
Hand fracture		
subjects affected / exposed	1 / 141 (0.71%)	0 / 142 (0.00%)
occurrences (all)	1	0
Humerus fracture		
subjects affected / exposed	1 / 141 (0.71%)	1 / 142 (0.70%)
occurrences (all)	1	1
Post procedural complication		
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)
occurrences (all)	0	1
Post-traumatic pain		
subjects affected / exposed	1 / 141 (0.71%)	0 / 142 (0.00%)
occurrences (all)	1	0
Procedural pain		
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)
occurrences (all)	0	1
Radius fracture		
subjects affected / exposed	2 / 141 (1.42%)	0 / 142 (0.00%)
occurrences (all)	2	0
Spinal column injury		

subjects affected / exposed occurrences (all)	0 / 141 (0.00%) 0	1 / 142 (0.70%) 1	
Tooth injury subjects affected / exposed occurrences (all)	0 / 141 (0.00%) 0	1 / 142 (0.70%) 1	
Cardiac disorders			
Bundle branch block right subjects affected / exposed occurrences (all)	0 / 141 (0.00%) 0	1 / 142 (0.70%) 1	
Myocardial ischaemia subjects affected / exposed occurrences (all)	0 / 141 (0.00%) 0	1 / 142 (0.70%) 1	
Palpitations subjects affected / exposed occurrences (all)	2 / 141 (1.42%) 2	0 / 142 (0.00%) 0	
Ventricular pre-excitation subjects affected / exposed occurrences (all)	1 / 141 (0.71%) 1	0 / 142 (0.00%) 0	
Nervous system disorders			
Headache subjects affected / exposed occurrences (all)	3 / 141 (2.13%) 4	9 / 142 (6.34%) 13	
Dementia subjects affected / exposed occurrences (all)	1 / 141 (0.71%) 1	0 / 142 (0.00%) 0	
Dizziness subjects affected / exposed occurrences (all)	2 / 141 (1.42%) 2	1 / 142 (0.70%) 1	
Paraesthesia subjects affected / exposed occurrences (all)	1 / 141 (0.71%) 1	0 / 142 (0.00%) 0	
Post herpetic neuralgia subjects affected / exposed occurrences (all)	0 / 141 (0.00%) 0	1 / 142 (0.70%) 1	
Sciatica			

subjects affected / exposed occurrences (all)	1 / 141 (0.71%) 1	1 / 142 (0.70%) 1	
Transient ischaemic attack subjects affected / exposed occurrences (all)	1 / 141 (0.71%) 1	0 / 142 (0.00%) 0	
Blood and lymphatic system disorders			
Leukocytosis subjects affected / exposed occurrences (all)	0 / 141 (0.00%) 0	1 / 142 (0.70%) 1	
Leukopenia subjects affected / exposed occurrences (all)	4 / 141 (2.84%) 4	0 / 142 (0.00%) 0	
Neutropenia subjects affected / exposed occurrences (all)	2 / 141 (1.42%) 2	2 / 142 (1.41%) 2	
Normocytic anaemia subjects affected / exposed occurrences (all)	0 / 141 (0.00%) 0	1 / 142 (0.70%) 2	
Ear and labyrinth disorders			
Ear congestion subjects affected / exposed occurrences (all)	0 / 141 (0.00%) 0	1 / 142 (0.70%) 1	
Tinnitus subjects affected / exposed occurrences (all)	1 / 141 (0.71%) 1	0 / 142 (0.00%) 0	
Vertigo subjects affected / exposed occurrences (all)	0 / 141 (0.00%) 0	1 / 142 (0.70%) 1	
Eye disorders			
Age-related macular degeneration subjects affected / exposed occurrences (all)	1 / 141 (0.71%) 1	0 / 142 (0.00%) 0	
Blepharitis subjects affected / exposed occurrences (all)	0 / 141 (0.00%) 0	1 / 142 (0.70%) 1	
Cataract			

subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)	
occurrences (all)	0	1	
Dry eye			
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)	
occurrences (all)	0	1	
Entropion			
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)	
occurrences (all)	0	1	
Macular degeneration			
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)	
occurrences (all)	0	1	
Ocular hyperaemia			
subjects affected / exposed	1 / 141 (0.71%)	0 / 142 (0.00%)	
occurrences (all)	1	0	
Swelling of eyelid			
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)	
occurrences (all)	0	1	
Vision blurred			
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)	
occurrences (all)	0	1	
Visual impairment			
subjects affected / exposed	1 / 141 (0.71%)	0 / 142 (0.00%)	
occurrences (all)	1	0	
Gastrointestinal disorders			
Abdominal distension			
subjects affected / exposed	1 / 141 (0.71%)	0 / 142 (0.00%)	
occurrences (all)	1	0	
Abdominal pain			
subjects affected / exposed	1 / 141 (0.71%)	2 / 142 (1.41%)	
occurrences (all)	1	2	
Abdominal pain lower			
subjects affected / exposed	1 / 141 (0.71%)	0 / 142 (0.00%)	
occurrences (all)	1	0	
Abdominal pain upper			
subjects affected / exposed	0 / 141 (0.00%)	3 / 142 (2.11%)	
occurrences (all)	0	3	

Colitis		
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)
occurrences (all)	0	1
Constipation		
subjects affected / exposed	1 / 141 (0.71%)	2 / 142 (1.41%)
occurrences (all)	1	2
Dental cyst		
subjects affected / exposed	1 / 141 (0.71%)	0 / 142 (0.00%)
occurrences (all)	1	0
Diaphragmatic hernia		
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)
occurrences (all)	0	1
Diarrhoea		
subjects affected / exposed	5 / 141 (3.55%)	1 / 142 (0.70%)
occurrences (all)	5	1
Diverticulum intestinal		
subjects affected / exposed	0 / 141 (0.00%)	2 / 142 (1.41%)
occurrences (all)	0	2
Dry mouth		
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)
occurrences (all)	0	1
Gastritis		
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)
occurrences (all)	0	1
Gastrooesophageal reflux disease		
subjects affected / exposed	1 / 141 (0.71%)	2 / 142 (1.41%)
occurrences (all)	1	2
Gingival pain		
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)
occurrences (all)	0	1
Hiatus hernia		
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)
occurrences (all)	0	1
Irritable bowel syndrome		
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)
occurrences (all)	0	1



Large intestine polyp subjects affected / exposed occurrences (all)	1 / 141 (0.71%) 1	0 / 142 (0.00%) 0	
Nausea subjects affected / exposed occurrences (all)	2 / 141 (1.42%) 2	2 / 142 (1.41%) 2	
Oesophageal ulcer subjects affected / exposed occurrences (all)	0 / 141 (0.00%) 0	1 / 142 (0.70%) 1	
Oral mucosal blistering subjects affected / exposed occurrences (all)	0 / 141 (0.00%) 0	1 / 142 (0.70%) 2	
Stomatitis subjects affected / exposed occurrences (all)	1 / 141 (0.71%) 1	0 / 142 (0.00%) 0	
Toothache subjects affected / exposed occurrences (all)	1 / 141 (0.71%) 1	0 / 142 (0.00%) 0	
Vomiting subjects affected / exposed occurrences (all)	0 / 141 (0.00%) 0	2 / 142 (1.41%) 2	
Hepatobiliary disorders Hypertransaminasaemia subjects affected / exposed occurrences (all)	1 / 141 (0.71%) 1	0 / 142 (0.00%) 0	
Skin and subcutaneous tissue disorders Decubitus ulcer subjects affected / exposed occurrences (all)	0 / 141 (0.00%) 0	1 / 142 (0.70%) 1	
Dermal cyst subjects affected / exposed occurrences (all)	0 / 141 (0.00%) 0	1 / 142 (0.70%) 1	
Dermatitis subjects affected / exposed occurrences (all)	0 / 141 (0.00%) 0	1 / 142 (0.70%) 1	
Dermatitis allergic			

subjects affected / exposed	1 / 141 (0.71%)	0 / 142 (0.00%)	
occurrences (all)	1	0	
Dry skin			
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)	
occurrences (all)	0	1	
Pruritus			
subjects affected / exposed	1 / 141 (0.71%)	1 / 142 (0.70%)	
occurrences (all)	1	3	
Pruritus generalised			
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)	
occurrences (all)	0	1	
Rash			
subjects affected / exposed	4 / 141 (2.84%)	1 / 142 (0.70%)	
occurrences (all)	4	1	
Rash pruritic			
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)	
occurrences (all)	0	1	
Swelling face			
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)	
occurrences (all)	0	1	
Renal and urinary disorders			
Micturition urgency			
subjects affected / exposed	1 / 141 (0.71%)	0 / 142 (0.00%)	
occurrences (all)	1	0	
Renal cyst			
subjects affected / exposed	1 / 141 (0.71%)	0 / 142 (0.00%)	
occurrences (all)	1	0	
Renal failure			
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)	
occurrences (all)	0	1	
Urinary incontinence			
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)	
occurrences (all)	0	1	
Endocrine disorders			
Hypothyroidism			

subjects affected / exposed	2 / 141 (1.42%)	0 / 142 (0.00%)	
occurrences (all)	2	0	
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	7 / 141 (4.96%)	9 / 142 (6.34%)	
occurrences (all)	8	12	
Arthritis			
subjects affected / exposed	1 / 141 (0.71%)	0 / 142 (0.00%)	
occurrences (all)	1	0	
Back pain			
subjects affected / exposed	2 / 141 (1.42%)	3 / 142 (2.11%)	
occurrences (all)	2	4	
Bone pain			
subjects affected / exposed	3 / 141 (2.13%)	1 / 142 (0.70%)	
occurrences (all)	3	1	
Bursitis			
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)	
occurrences (all)	0	1	
Muscle spasms			
subjects affected / exposed	1 / 141 (0.71%)	2 / 142 (1.41%)	
occurrences (all)	1	2	
Muscular weakness			
subjects affected / exposed	1 / 141 (0.71%)	0 / 142 (0.00%)	
occurrences (all)	1	0	
Musculoskeletal pain			
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)	
occurrences (all)	0	1	
Musculoskeletal stiffness			
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)	
occurrences (all)	0	1	
Myalgia			
subjects affected / exposed	2 / 141 (1.42%)	1 / 142 (0.70%)	
occurrences (all)	2	1	
Neck pain			

subjects affected / exposed	1 / 141 (0.71%)	0 / 142 (0.00%)	
occurrences (all)	1	0	
Nodal osteoarthritis			
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)	
occurrences (all)	0	1	
Osteoarthritis			
subjects affected / exposed	1 / 141 (0.71%)	0 / 142 (0.00%)	
occurrences (all)	1	0	
Pain in extremity			
subjects affected / exposed	4 / 141 (2.84%)	3 / 142 (2.11%)	
occurrences (all)	4	5	
Plantar fasciitis			
subjects affected / exposed	2 / 141 (1.42%)	0 / 142 (0.00%)	
occurrences (all)	2	0	
Rheumatoid arthritis			
subjects affected / exposed	1 / 141 (0.71%)	0 / 142 (0.00%)	
occurrences (all)	1	0	
Spinal osteoarthritis			
subjects affected / exposed	2 / 141 (1.42%)	1 / 142 (0.70%)	
occurrences (all)	2	1	
Spinal pain			
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)	
occurrences (all)	0	1	
Spondylitis			
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)	
occurrences (all)	0	1	
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	15 / 141 (10.64%)	10 / 142 (7.04%)	
occurrences (all)	16	10	
Upper respiratory tract infection			
subjects affected / exposed	2 / 141 (1.42%)	8 / 142 (5.63%)	
occurrences (all)	2	8	
Bacterial vulvovaginitis			
subjects affected / exposed	1 / 141 (0.71%)	0 / 142 (0.00%)	
occurrences (all)	1	0	

Bronchitis		
subjects affected / exposed	4 / 141 (2.84%)	6 / 142 (4.23%)
occurrences (all)	4	8
Cystitis		
subjects affected / exposed	3 / 141 (2.13%)	0 / 142 (0.00%)
occurrences (all)	3	0
Ear infection		
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)
occurrences (all)	0	1
Furuncle		
subjects affected / exposed	1 / 141 (0.71%)	0 / 142 (0.00%)
occurrences (all)	1	0
Gastroenteritis		
subjects affected / exposed	1 / 141 (0.71%)	1 / 142 (0.70%)
occurrences (all)	1	1
Genital herpes		
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)
occurrences (all)	0	1
Herpes virus infection		
subjects affected / exposed	0 / 141 (0.00%)	2 / 142 (1.41%)
occurrences (all)	0	2
Herpes zoster		
subjects affected / exposed	1 / 141 (0.71%)	1 / 142 (0.70%)
occurrences (all)	1	1
Hordeolum		
subjects affected / exposed	1 / 141 (0.71%)	1 / 142 (0.70%)
occurrences (all)	1	1
Influenza		
subjects affected / exposed	1 / 141 (0.71%)	0 / 142 (0.00%)
occurrences (all)	1	0
Laryngitis		
subjects affected / exposed	1 / 141 (0.71%)	1 / 142 (0.70%)
occurrences (all)	1	1
Lower respiratory tract infection		
subjects affected / exposed	1 / 141 (0.71%)	0 / 142 (0.00%)
occurrences (all)	1	0

Lung abscess		
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)
occurrences (all)	0	1
Oral herpes		
subjects affected / exposed	2 / 141 (1.42%)	1 / 142 (0.70%)
occurrences (all)	2	1
Pharyngitis		
subjects affected / exposed	1 / 141 (0.71%)	0 / 142 (0.00%)
occurrences (all)	1	0
Pharyngitis streptococcal		
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)
occurrences (all)	0	1
Pneumonia		
subjects affected / exposed	1 / 141 (0.71%)	0 / 142 (0.00%)
occurrences (all)	1	0
Respiratory tract infection		
subjects affected / exposed	2 / 141 (1.42%)	2 / 142 (1.41%)
occurrences (all)	2	2
Rhinitis		
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)
occurrences (all)	0	1
Sinusitis		
subjects affected / exposed	2 / 141 (1.42%)	1 / 142 (0.70%)
occurrences (all)	2	1
Tonsillitis		
subjects affected / exposed	1 / 141 (0.71%)	0 / 142 (0.00%)
occurrences (all)	1	0
Tooth infection		
subjects affected / exposed	1 / 141 (0.71%)	0 / 142 (0.00%)
occurrences (all)	1	0
Tooth abscess		
subjects affected / exposed	1 / 141 (0.71%)	1 / 142 (0.70%)
occurrences (all)	1	1
Urethritis		
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)
occurrences (all)	0	1

Urinary tract infection			
subjects affected / exposed	4 / 141 (2.84%)	4 / 142 (2.82%)	
occurrences (all)	4	4	
Urinary tract infection bacterial			
subjects affected / exposed	1 / 141 (0.71%)	0 / 142 (0.00%)	
occurrences (all)	1	0	
Viral infection			
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)	
occurrences (all)	0	1	
Viral labyrinthitis			
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)	
occurrences (all)	0	1	
Viral upper respiratory tract infection			
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)	
occurrences (all)	0	1	
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)	
occurrences (all)	0	1	
Glucose tolerance impaired			
subjects affected / exposed	1 / 141 (0.71%)	0 / 142 (0.00%)	
occurrences (all)	1	0	
Hyperglycaemia			
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)	
occurrences (all)	0	1	
Hyperlipidaemia			
subjects affected / exposed	1 / 141 (0.71%)	0 / 142 (0.00%)	
occurrences (all)	1	0	
Hypoalbuminaemia			
subjects affected / exposed	1 / 141 (0.71%)	0 / 142 (0.00%)	
occurrences (all)	1	0	
Hypocalcaemia			
subjects affected / exposed	1 / 141 (0.71%)	1 / 142 (0.70%)	
occurrences (all)	1	1	
Hypokalaemia			

subjects affected / exposed	1 / 141 (0.71%)	2 / 142 (1.41%)	
occurrences (all)	1	2	
Hyponatraemia			
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)	
occurrences (all)	0	1	
Malnutrition			
subjects affected / exposed	0 / 141 (0.00%)	1 / 142 (0.70%)	
occurrences (all)	0	1	
Type 2 diabetes mellitus			
subjects affected / exposed	1 / 141 (0.71%)	0 / 142 (0.00%)	
occurrences (all)	1	0	



## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported